Lyell Immunopharma, Inc.
LYEL
$12.86
$0.161.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -66.67% | -60.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -66.67% | -60.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -66.67% | -60.00% | |||
| SG&A Expenses | -9.99% | -0.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -42.45% | 16.34% | |||
| Total Operating Expenses | -28.01% | 64.98% | |||
| Operating Income | 28.01% | -65.03% | |||
| Income Before Tax | 82.84% | -262.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 82.84% | -262.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 82.84% | -262.26% | |||
| EBIT | 28.01% | -65.03% | |||
| EBITDA | 29.03% | -70.33% | |||
| EPS Basic | 83.90% | -222.56% | |||
| Normalized Basic EPS | 70.30% | -74.82% | |||
| EPS Diluted | 83.90% | -222.56% | |||
| Normalized Diluted EPS | 70.30% | -74.82% | |||
| Average Basic Shares Outstanding | 6.63% | 12.31% | |||
| Average Diluted Shares Outstanding | 6.63% | 12.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||